Akums Drugs And Pharmaceuticals Limited · NSE:AKUMS
Akums Drugs And Pharmaceuticals — Q3 FY26 Earnings Presentation
19 slides from Akums Drugs And Pharmaceuticals's earnings presentation, Feb 13, 2026
Slide 1: Exchange filing cover letter - Regulation 30 disclosure
Ref: Akums/Exchange/2025-26/79 February 13, 2026 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd BSE Limited Exchange Plaza, C-1, Block G, Rotunda Building, Phiroze Jeejeebhoy Bandra Kurla Complex, Towers, Dalal Street, Fort, Mumbai – Bandra (E),Mumbai – 40
Slide 2: Q3 and 9M FY 25-26 Earnings Presentation
Q3 and 9M FY 25-26 Earnings Presentation February 2026
Slide 3: Disclaimer
Disclaimer Akums Drugs and Pharmaceuticals Limited may, from time to time, make written and oral forward-looking statements, in addition to statements contained in the company's filings with BSE Limited (BSE) and National Stock Exchange of India Limited (NSE), and its reports to shareholders. The co
Slide 4: Managing Directors' Message
Managing Directors’ Message Dear Investors We are pleased to declare the results for Q3FY26 as well as 9MFY26. Q3 FY26 was a strong quarter for Akums. Our healthy operating performance was characterized by strong execution across multiple key segments. CDMO registered a healthy topline growth of mor
Slide 5: Two Decades' Legacy of Expertise, Experience & Trust
Two Decades’ Legacy of Expertise, Experience & Trust Dedicated facilities for Expanded into Asian markets. Hormones, Cosmetics Established dedicated and Dermatology. Acquired Established R&D lab in Mumbai to Parabolic Drugs to manufacturing site for Launched Akumentis to venture into regulated marke
Slide 6: Technologically Advanced Manufacturing Capabilities
Technologically Advanced Manufacturing Capabilities Location Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Kotdwar Baddi Haridwar Year 2004 2007 2007 2010 2010 2010 2014 2014 2021 2023 2024 Annual Capacity (Cr units) 649 15 39 244 6 252 2.603 732 17 368 36 Ayurvedic / β-lac
Slide 7: R&D Focus
R&D Focus Illustrative Tablet Bi-layered, Inlay Multiple Tablets Pre-filled In Tablet Sustained Release Tablet in Capsule syringes Tablet in Tablet Lyophilized Smart Gummies Mouth Melting Tri Layered Vials Tablets Powders in Sachet Tablet Innovative In-house Technologies (1) As of 31st March 2025 6
Slide 8: Key drivers as well as their trends during Q3FY26
Key drivers as well as their trends during Q3FY26 Key drivers and their impact on Akums’ performance API prices Strong volume continue to Operating Strong growth, despite remain soft leverage and performance in muted volumes though initial ramp up of new branded exports in the IPM signs of facilitie
Slide 9: Financial Performance Highlights
Q3 FY 26 Financial Performance Highlights 8
Slide 10: Q3FY26 Performance Highlights
Q3FY26 Performance Highlights Consolidated Performance* Segment Break-up Share in Q3 FY26 181 cr 68 cr Business Vertical revenue 1,194 cr 121 cr 54 cr 1,050 cr 15.2% 5.7% CDMO 79.0% 11.6% 5.1% Domestic Branded Total Income EBITDA PAT 9.9% Formulation Total Income (+16.5% YoY) Adj. EBITDA (+33.3% YoY
Slide 11: 9MFY26 Performance Highlights
9MFY26 Performance Highlights Consolidated Performance* Segment Break-up Share in 9M FY26 464 cr 175 cr Business Vertical revenue 3,295 cr 121 cr 54 cr 1,050 cr 14.1% 5.3% CDMO 79.1% 11.6% 5.1% Domestic Branded Total Income Adj. EBITDA Adj PAT 10.8% Formulation Total Income (+6.4% YoY) Adj. EBITDA (
Slide 12: Profit and Loss Statement
Profit and Loss Statement Particulars (Rs Cr) Q3 FY26 Q3 FY25 Y-O-Y (%) Q2 FY26 Q-O-Q (%) 9M FY26 9M FY25 Y-O-Y (%) Revenue 1,160 1,010 14.8% 1,018 14.0% 3,201 3,063 4.5% COGS 679 602 12.6% 593 14.5% 1,853 1,794 3.3% GP Margin % 41.5% 40.4% 41.8% 42.1% 41.4% Employee Expenses 189 176 7.8% 189 0.1% 5
Slide 13: Quarterly Performance Trends
Quarterly Performance Trends Revenue (INR Cr.) Adjusted EBITDA1 (INR Cr) Adjusted PAT2# (INR Cr) Margin % Margin % 12.0% 8.9% 12.6% 9.3% 12.7% 6.5% 4.1% 6.2% 4.1% 7.2% 14.8% 21.0% 29.5 % 1,160 1,056 86 1,010 1,024 1,018 147 129 66 65 121 94 94 44 43 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q3 FY25 Q4
Slide 14: 9M Performance Trends
9M Performance Trends Revenue (INR Cr.) Adjusted EBITDA1 (INR Cr) Adjusted PAT2# (INR Cr) Margin % Margin % 12.0% 11.6% 6.1% 5.9% 4.5% 1.0% 1.6% 3,201 3,063 367 370 190 193 9M FY25 9M FY26 9M FY25 9M FY26 9M FY25 9M FY26 (1 -Adjusted EBITDA = Profit before tax + fair value changes to financial instr
Slide 15: Revenue and Margin Deep-Dive – Quarterly
Revenue and Margin Deep-Dive – Quarterly Revenue (INR Cr.) Adj EBIDTA % CDMO Revenue (INR Cr.) • Revenue growth driven by CDMO and • Operating leverage led improvement in gross • Strong double digit volume growth International formulations margins and employee expenses • Erosion in API prices respon
Slide 16: Revenue and Margin Deep-Dive – 9M
Revenue and Margin Deep-Dive – 9M Revenue (INR Cr.) Adj EBIDTA % CDMO Revenue (INR Cr.) • 9M revenue growth driven by improved • Operating leverage led improvement in gross • Volumes grew despite muted volumes in the volumes in CDMO margins IPM • Erosion in API prices and consolidation in • Other ex
Slide 17: Segmental Quarterly Performance
Segmental Quarterly Performance Domestic Branded International Branded Trade CDMO Revenue API Revenue Formulation Revenue Formulation Revenue Generics Revenue QoQ 13.8% YoY 16.3% QoQ -5.8% YoY 4.2% QoQ 123% YoY 18.0% QoQ 1.7% YoY -18.0% QoQ 22.0% YoY 35.4% 916 54 787 804 122 115 50 110 42 30 44 24 2
Slide 18: Segmental 9M Performance
Segmental 9M Performance Domestic Branded International Branded Trade CDMO Revenue API Revenue Formulation Revenue Formulation Revenue Generics Revenue YoY 7.0% YoY 4.3% YoY 4.6% YoY -21.8% YoY -15.0% 2,533 2,368 169 344 103 108 92 330 72 144 9M FY25 9M FY26 9M FY25 9M FY26 9M FY25 9M FY26 9M FY25 9
Slide 19: Thank You
Thank You For further information, contact: IR Desk Akums Drugs and Pharmaceuticals Ltd Email: investors@akums.net/ankit.jain@akums.net Siddharth Rangnekar / Shruti Joshi CDR, India Tel: +91 97699 19966 / 75065 67349 Email: siddharth@cdr-india.com / shruti@cdr-india.com 18
Akums Drugs and Pharmaceuticals — Q3 FY26 Earnings Presentation on 6ix